Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Photocoagulation is the standard treatment in the focal EMCS, disrupts vascular leakage and
allows the pigment epithelium remove the intraretinal fluid is effective in reducing the
incidence of visual loss but can reduce contrast sensitivity and retinal sensitivity, the
characteristics of the function can be reduced such as setting (location and stability) are
relevant to the quality of the patient's vision parameters, reading comprehension, especially
the ability, duration of diabetic macular edema, could have a significant impact on survival
and / or the functional reserve of the macular cells subjected to mechanical and toxic
stress-induced edema. It seems that in the treatment of patients with EMCS, photoreceptor
damage occurs as a recent phenomenon, and can precede neurodegeneration retinal photoreceptor
loss, whereby visual function can be decreased. An adjunctive treatment as Dorzolamide
facilitating effect helping resorption of intraretinal fluid through EPR and reduce adverse
events that is the loss of contrast sensitivity and retinal sensitivity, response time of
photocoagulation treatment could be reduced to the patient, because the rate of resorption of
intraretinal fluid is facilitated and thus the duration of the response, also could reduce
damage to vision caused by the inadequacies of the photoreceptors during the evolution of
macular edema avoiding moderate visual loss, there by increasing the quality of life in terms
of improving the quality of vision in diabetic patients. In addition to obtaining a specific
adjuvant treatment with photocoagulation is helpful for focal edema in diabetic and a new
level using dorzolamide in retina Dorzolamide as adjunctive therapy after focal
photocoagulation is more effective than placebo in improving visual function in patients with
diabetic macular edema